Definitive radiation therapy for localized prostatic adenocarcinoma

Giorgio Arcangeli, ADriana Micheli, Giancarlo Arcangeli, Vito Pansadoro, Francesco De Paula, Diana Giannarelli, Marcello Benassi

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

From 1974 to 1987, a total of 199 patients with prostatic carcinoma localized to the pelvis were treated with definitive external beam radiation therapy at the Istituto Medico e di Ricerca Scientifica. The median follow-up for all 126 surviving patients was 60 months. Actuarial 5- (and 10-) year overall survival rates for U.I.C.C. clinical Stage T1-2, T3 and T4 disease were 76.1% (58.5), 66% (42.5), and 27.6%, respectively. The corresponding 5- (and 10-) year disease-specific survival rates were 81.7% (73), 72.5% (57.4), and 36.2%. The corresponding values of disease-free survival were 81.3% (76.8), 59.2% (57), and 17%, respectively. In 120 patients with more than 5 years of follow-up, local failure was seen alone in eight patients (6.6%) and associated with distant metastases in 19 patients (15.8%). In 28 patients (23.3%), distant metastases were observed alone. The median survival from the first evidence of metastases was 20 months, with no patient surviving beyond 5 years. The incidence of complications was acceptable. Serious complications, consisting of stenosis of both ureters and sigmoid colon requiring both urinary and intestinal diversion, occured in two patients (1.3%). This study reveals that external radiotherapy is an efficacious and safe modality for locoregional control of prostate cancer.

Original languageEnglish
Pages (from-to)439-446
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume20
Issue number3
DOIs
Publication statusPublished - 1991

Fingerprint

radiation therapy
Adenocarcinoma
Radiotherapy
metastasis
Neoplasm Metastasis
Survival Rate
cancer
pelvis
Urinary Diversion
Sigmoid Colon
Ureter
Pelvis
Disease-Free Survival
Prostatic Neoplasms
Pathologic Constriction
incidence
Carcinoma
Survival
Incidence

Keywords

  • Prognostic factors
  • Prostatic carcinoma
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Definitive radiation therapy for localized prostatic adenocarcinoma. / Arcangeli, Giorgio; Micheli, ADriana; Arcangeli, Giancarlo; Pansadoro, Vito; Paula, Francesco De; Giannarelli, Diana; Benassi, Marcello.

In: International Journal of Radiation Oncology Biology Physics, Vol. 20, No. 3, 1991, p. 439-446.

Research output: Contribution to journalArticle

Arcangeli, Giorgio ; Micheli, ADriana ; Arcangeli, Giancarlo ; Pansadoro, Vito ; Paula, Francesco De ; Giannarelli, Diana ; Benassi, Marcello. / Definitive radiation therapy for localized prostatic adenocarcinoma. In: International Journal of Radiation Oncology Biology Physics. 1991 ; Vol. 20, No. 3. pp. 439-446.
@article{e21d0349a72641c293a2ac2ec5470a0f,
title = "Definitive radiation therapy for localized prostatic adenocarcinoma",
abstract = "From 1974 to 1987, a total of 199 patients with prostatic carcinoma localized to the pelvis were treated with definitive external beam radiation therapy at the Istituto Medico e di Ricerca Scientifica. The median follow-up for all 126 surviving patients was 60 months. Actuarial 5- (and 10-) year overall survival rates for U.I.C.C. clinical Stage T1-2, T3 and T4 disease were 76.1{\%} (58.5), 66{\%} (42.5), and 27.6{\%}, respectively. The corresponding 5- (and 10-) year disease-specific survival rates were 81.7{\%} (73), 72.5{\%} (57.4), and 36.2{\%}. The corresponding values of disease-free survival were 81.3{\%} (76.8), 59.2{\%} (57), and 17{\%}, respectively. In 120 patients with more than 5 years of follow-up, local failure was seen alone in eight patients (6.6{\%}) and associated with distant metastases in 19 patients (15.8{\%}). In 28 patients (23.3{\%}), distant metastases were observed alone. The median survival from the first evidence of metastases was 20 months, with no patient surviving beyond 5 years. The incidence of complications was acceptable. Serious complications, consisting of stenosis of both ureters and sigmoid colon requiring both urinary and intestinal diversion, occured in two patients (1.3{\%}). This study reveals that external radiotherapy is an efficacious and safe modality for locoregional control of prostate cancer.",
keywords = "Prognostic factors, Prostatic carcinoma, Radiation therapy",
author = "Giorgio Arcangeli and ADriana Micheli and Giancarlo Arcangeli and Vito Pansadoro and Paula, {Francesco De} and Diana Giannarelli and Marcello Benassi",
year = "1991",
doi = "10.1016/0360-3016(91)90055-9",
language = "English",
volume = "20",
pages = "439--446",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Definitive radiation therapy for localized prostatic adenocarcinoma

AU - Arcangeli, Giorgio

AU - Micheli, ADriana

AU - Arcangeli, Giancarlo

AU - Pansadoro, Vito

AU - Paula, Francesco De

AU - Giannarelli, Diana

AU - Benassi, Marcello

PY - 1991

Y1 - 1991

N2 - From 1974 to 1987, a total of 199 patients with prostatic carcinoma localized to the pelvis were treated with definitive external beam radiation therapy at the Istituto Medico e di Ricerca Scientifica. The median follow-up for all 126 surviving patients was 60 months. Actuarial 5- (and 10-) year overall survival rates for U.I.C.C. clinical Stage T1-2, T3 and T4 disease were 76.1% (58.5), 66% (42.5), and 27.6%, respectively. The corresponding 5- (and 10-) year disease-specific survival rates were 81.7% (73), 72.5% (57.4), and 36.2%. The corresponding values of disease-free survival were 81.3% (76.8), 59.2% (57), and 17%, respectively. In 120 patients with more than 5 years of follow-up, local failure was seen alone in eight patients (6.6%) and associated with distant metastases in 19 patients (15.8%). In 28 patients (23.3%), distant metastases were observed alone. The median survival from the first evidence of metastases was 20 months, with no patient surviving beyond 5 years. The incidence of complications was acceptable. Serious complications, consisting of stenosis of both ureters and sigmoid colon requiring both urinary and intestinal diversion, occured in two patients (1.3%). This study reveals that external radiotherapy is an efficacious and safe modality for locoregional control of prostate cancer.

AB - From 1974 to 1987, a total of 199 patients with prostatic carcinoma localized to the pelvis were treated with definitive external beam radiation therapy at the Istituto Medico e di Ricerca Scientifica. The median follow-up for all 126 surviving patients was 60 months. Actuarial 5- (and 10-) year overall survival rates for U.I.C.C. clinical Stage T1-2, T3 and T4 disease were 76.1% (58.5), 66% (42.5), and 27.6%, respectively. The corresponding 5- (and 10-) year disease-specific survival rates were 81.7% (73), 72.5% (57.4), and 36.2%. The corresponding values of disease-free survival were 81.3% (76.8), 59.2% (57), and 17%, respectively. In 120 patients with more than 5 years of follow-up, local failure was seen alone in eight patients (6.6%) and associated with distant metastases in 19 patients (15.8%). In 28 patients (23.3%), distant metastases were observed alone. The median survival from the first evidence of metastases was 20 months, with no patient surviving beyond 5 years. The incidence of complications was acceptable. Serious complications, consisting of stenosis of both ureters and sigmoid colon requiring both urinary and intestinal diversion, occured in two patients (1.3%). This study reveals that external radiotherapy is an efficacious and safe modality for locoregional control of prostate cancer.

KW - Prognostic factors

KW - Prostatic carcinoma

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0026090626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026090626&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(91)90055-9

DO - 10.1016/0360-3016(91)90055-9

M3 - Article

C2 - 1995529

AN - SCOPUS:0026090626

VL - 20

SP - 439

EP - 446

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -